Monoclonal gammopathy: The good, the bad and the ugly

被引：43

作者：

Glavey, Siobhan V. ^{[1
]}

Leung, Nelson ^{[2
,3
]}

机构：

[1] Natl Univ Ireland, Dept Hematol, Galway, Ireland

[2] Mayo Clin, Div Nephrol & Hypertens, Dept Med, Rochester, MN USA

[3] Mayo Clin, Div Hematol, Dept Med, Rochester, MN USA

来源：

BLOOD REVIEWS | 2016年 / 30卷 / 03期

关键词：

Monoclonal gammopathy of uncertain; significance (MGUS); Renal; Amyloid; Infection; Monoclonal gammopathy of renal; significance (MGRS); VON-WILLEBRAND-SYNDROME; STEM-CELL TRANSPLANTATION; CHAIN DEPOSITION DISEASE; OF-THE-LITERATURE; PRIMARY SYSTEMIC AMYLOIDOSIS; CHRONIC LYMPHOCYTIC-LEUKEMIA; ACUTE-RENAL-FAILURE; HIGH-DOSE MELPHALAN; UNDETERMINED SIGNIFICANCE; MULTIPLE-MYELOMA;

D O I：

10.1016/j.blre.2015.12.001

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

Monoclonal gammopathy of undetermined significance (MGUS) is a condition characterized by the presence of a monoclonal gammopathy (MG) in which the clonal mass has not reached a predefined state in which the condition is considered malignant. It is a precursor to conditions such as multiple myeloma or lymphoma at a rate of Thus, from a hematologic standpoint, MGUS is a fairly benign condition. However, it is now recognized that organ damage resulting from just the MG without the need MM or lymphoma can occur. One of the most recognized is nephropathy secondary to monoclonal gammopathy of renal significance (MGRS). Other well-recognized conditions include neuropathies, oculopathies and dermopathies. Some conditions such as autoimmune diseases and coagulopathies are less common and recognized. Finally, systemic involvement of multiple organs is well described in several entities. In all of these conditions, the role of the MG is no longer insignificant. Thus, the term MGUS should be avoided when describing these entities. (C) 2015 Elsevier Ltd. All rights reserved.

引用

页码：223 / 231

页数：9

共 116 条

[1] Comparison of monoclonal gammopathy of undetermined significance-associated neuropathy and chronic inflammatory demyelinating polyneuropathy patients [J].